Pan-Cancer Early Detection
Clinical Trials
Early detection and treatment are important components of comprehensive cancer control. Cancer, when identified early, is more likely to respond to effective treatment, resulting in a greater probability of surviving as well as less expensive treatment.
Cancer is one of the major diseases that seriously threaten human health. 80% of cancer patients are diagnosed in middle and late stages, putting heavy economic burden on their families and society. As the population ages, it becomes even more challenging in prevention and treatment of cancer. Most early-stage cancer can be effectively treated through radical surgeries. Once cancer patients have clinically detectable metastasis, it will be difficult to be cured, and the patients

The 5-year cancer-related mortality in patients with distant metastatic cancer


The 5-year cancer-related mortality in patients with localized cancer

Early detection and early treatment of cancer will directly reduce the mortality and improve the overall survival of cancer patients
*SEER Program ( *Stat Database: Incidence - SEER 18 R egs Research Data, Nov 2018
Early Detection
Capturing early signals of cancer
before clinical symptoms appear
Comprehensive Inspection
Covering 6 major cancers with high
incidence and mortality in China
Precise Positioning
Accurately identifying signals of cancer,
locating invaded organs,
and guiding the following clinical examinations
Safe and Convenient
Easy to operate, time-saving,
and efficient in detecting hidden cancer;
Non-invasive, painless, and non-radioactive

6-cancer data released at the ESMO Asia Virtual Congress

Qiang Gao BL, Shangli Cai, et al. LBA3-Early detection and localization of multiple cancers using a blood-based methylation assay (ELSA-seq). ESMO Asia Virtual Congress 2020 (20-22 November). 2020.

Detection of cfDNA
methylation signals based
on liquid biopsy

High-throughput sequencing
covers 8,000+
methylation sites,
fully covering cancer signals

The cfDNA level in early-stage cancer patients
is low, how can we build a stable database?
BRELSA ® Technology
We have world-leading technologies to enable
high-efficiency isolation of low-volume cfDNA,
starting with 500 pg cfDNA.
There are multiple repetitive-element regions where DNA methylation occurs
how can we accurately capture it?
We’ve designed a multi-layer structure for
methylation probes, which can help accurately
locate methylation in repetitive-element regions.
(The clinical study has been approved by the China Human Genetic Resources Administration Office.)
Pan-canceR Early DetectIon projeCT
Leading site:Zhongshan Hospital, Fudan University
Principal investigator:Professor Fan Jia, Fellow of the Chinese Academy of Sciences and President of Shanghai Zhongshan Hospital
Cancer types covered:multiple cancers with high incidence and mortality in China, including liver cancer, lung cancer, pancreatic cancer, ovarian cancer, colorectal cancer, esophageal cancer, gastric cancer, cholangiocarcinoma, head and neck cancer, etc.
Participants:14,026 cases
Research highlights:The PREDICT study is the first prospective, blind-validated, pan-cancer early detection study in China, enrolling more than 10,000 participants . The study has for the first time comprehensively explored cfDNA methylation, together with serum tumor markers and blood RNA. The study will optimize and evaluate the sensitivity, specificity and TOO of cfDNA methylation-based pan-cancer early detection in patients with multiple cancers.
(The clinical study has been approved by the China Human Genetic Resources Administration Office.)
Pan-canceR Early-Stage deteCtion by lIquid biopsy tEchNique projecT
Leading site:Cancer Hospital of the Chinese Academy of Medical Sciences
Principal investigator:Professor He Jie, Fellow of the Chinese Academy of Sciences and head of the China National Cancer Center; Professor Wang Jie
Cancer types covered:22 cancer types, including those with high incidence and mortality in China, as well as some rare cancers
Participants:11,879 cases
Research highlights:Research highlights: The PRESCIENT study is the first prospective, pan-cancer early detection study based on liquid biopsy and multi-omics technique in China, enrolling more than 10,000 participants. It is part of the National Key Research and Development Program — Research & Development and Evaluation of Liquid Biopsy Technique for Early-Stage Screening and Diagnosis of Malignant Tumors — undertaken by Cancer Hospital, Chinese Academy of Medical Sciences (project ID: 2019YFC131570). The study will promote the development of pan-cancer early detection and screening technologies in China, and will help identify the specific epigenetic characteristics of cancer patients with different etiologies and pathologies.
Leading Sites
Participating Sites
燃石早检服务热线: 4000159966
(工作时间:工作日 09:00-18:00)